Bionxt Solutions’ experimental sublingual therapy BNT23001 led to about 40% higher blood exposure to cladribine than a conventional oral tablet formulation, such as those used in multiple sclerosis (MS) therapies like Mavenclad, the company reported. The results come from a preclinical study in adult miniature pigs, an animal model often used in drug research. Bionxt […]
The post Dissolvable film may deliver more MS medicine than standard tablets appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com